Should You Buy Pfizer Stock in 2025? A Guide for Filipinos
Is it the right time to buy Pfizer?
ScorePfizer, a cornerstone of the global pharmaceutical sector, is currently trading around $25.55, with substantial average daily volumes exceeding 44 million shares, indicating sustained investor engagement. While the market continues to adjust to the decline in COVID-19 related revenues, the company's recent performance demonstrates significant underlying strength. The latest quarterly earnings surpassed expectations, and its strategic cost-saving program is on track to deliver $4.5 billion in net savings. This proactive management allows for a greater focus on its core growth areas. This strategic shift is fueling a constructive market sentiment, with investors increasingly looking beyond short-term headwinds to the company's robust long-term potential. For investors with a long-term horizon, this period of transition may represent a compelling opportunity. Reinforcing this view, a consensus of over 15 leading national and international banks has established a price target of approximately $33.22, reflecting confidence in Pfizer's innovation and future growth trajectory.
- ✅Robust pipeline with over 100 innovative drug candidates.
- ✅Attractive and high dividend yield for income investors.
- ✅Global leader with a strong, trusted pharmaceutical brand.
- ✅Projected 10% operational growth for the coming year.
- ✅Significant cost-saving program enhancing future profitability.
- ❌Revenue adjustment from declining COVID-19 product sales.
- ❌Potential for regulatory pressure on drug pricing policies.
Score- ✅Robust pipeline with over 100 innovative drug candidates.
- ✅Attractive and high dividend yield for income investors.
- ✅Global leader with a strong, trusted pharmaceutical brand.
- ✅Projected 10% operational growth for the coming year.
- ✅Significant cost-saving program enhancing future profitability.
Is it the right time to buy Pfizer?
- ✅Robust pipeline with over 100 innovative drug candidates.
- ✅Attractive and high dividend yield for income investors.
- ✅Global leader with a strong, trusted pharmaceutical brand.
- ✅Projected 10% operational growth for the coming year.
- ✅Significant cost-saving program enhancing future profitability.
- ❌Revenue adjustment from declining COVID-19 product sales.
- ❌Potential for regulatory pressure on drug pricing policies.
Score- ✅Robust pipeline with over 100 innovative drug candidates.
- ✅Attractive and high dividend yield for income investors.
- ✅Global leader with a strong, trusted pharmaceutical brand.
- ✅Projected 10% operational growth for the coming year.
- ✅Significant cost-saving program enhancing future profitability.
- What is Pfizer?
- How much is Pfizer stock?
- Our full analysis of Pfizer stock
- How to Buy Pfizer Stock in the Philippines
- Our 7 Tips for Buying Pfizer Stock
- The latest news about Pfizer
- FAQ
- On the same topic
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Pfizer for over three years. Every month, hundreds of thousands of users in the Philippines trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Pfizer.
What is Pfizer?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | U.S.-based firm, active globally in pharmaceuticals. |
| 💼 Market | NYSE (New York Stock Exchange) | Highly liquid large-cap, well-covered on major global market. |
| 🏛️ ISIN code | US7170811035 | Enables international trading and portfolio diversification. |
| 👤 CEO | Albert Bourla | Led Pfizer’s R&D and vaccine strategy successfully. |
| 🏢 Market cap | $145.66 billion | Remains one of the largest pharma stocks by market value. |
| 📈 Revenue | $62.46 billion (TTM) | Revenue is pressured by post-COVID normalization trends. |
| 💹 EBITDA | $23.32 billion (TTM) | Strong cashflow supports dividend and investment capability. |
| 📊 P/E Ratio (Price/Earnings) | 18.57 | Attractive valuation for sector; potential for rerating. |
How much is Pfizer stock?
The price of Pfizer stock is slightly down this week. Pfizer is currently trading at $25.55 per share, a decrease of $0.07 (-0.27%) in the past 24 hours and a weekly change of -0.45%. The company’s market capitalization stands at $145.66 billion, with an average three-month daily volume of 44.2 million shares. Its P/E Ratio is 18.57, offering an attractive dividend yield of 6.76% and a stock beta of 0.49, which signals lower volatility than the broader market. This combination of steady yield and defensive profile may appeal to Philippine investors seeking global diversification.
Our full analysis of Pfizer stock
After thoroughly reviewing Pfizer’s latest financial results and its three-year stock performance, we have conducted a multi-dimensional analysis—leveraging proprietary algorithms that integrate financial metrics, technical signals, market data, and peer comparisons. This rigorous approach uncovers key strengths and forward drivers that shape Pfizer’s trajectory in today’s market. So, why might Pfizer stock once again become a strategic entry point into the global healthcare sector in 2025?
Recent performance and market context
Pfizer’s stock currently trades at $25.55, with a modest 5-day change of -0.45% and an intraday dip of 0.27%. While the past year saw a 7.83% decline, recent months reveal stabilization and signs of renewed interest. The market capitalization stands at an impressive $145.66 billion, reflecting the company’s enduring leadership in global pharmaceuticals. Analysts project operational growth for 2025, supported by long-term secular drivers like worldwide healthcare demand, expanded access in emerging markets, and growing investment in life sciences.
Recent positive developments add to the constructive outlook: Pfizer delivered an adjusted Q1 2025 EPS of $0.92, well above consensus expectations, and remains on track to achieve $4.5 billion in cost savings by year-end. The upcoming data readouts from a robust pipeline—including advances in oncology, vaccines, and rare disease therapies—continue to capture market attention. The sector’s macroeconomic backdrop is favorable, with healthcare stocks typically viewed as defensive assets, appealing to investors during bouts of volatility and providing diversification for Philippine portfolios.
Technical analysis
Technical signals for Pfizer are showing improving momentum and the potential for a bullish reversal. The 14-day RSI stands at 70.81, which typically signals an overbought scenario, yet could also reflect building positive sentiment. The MACD registers at 0.47 and is in positive territory, supporting the notion of a short-term uptrend. Notably, the stock trades above its 5-day ($25.32), 20-day ($24.51), 50-day ($23.65), and 200-day ($25.05) moving averages—all clear “buy” signals and evidence of upward price action.
Support is observed around $25.23/$25.07, with strong foundational demand at the $24.93 level. Immediate resistance lies at $25.53, $25.67, and $25.83. This positioning just below resistance suggests limited downside risk and the opportunity for upward “breakout” moves, especially as results and late-stage data catalysts approach in Q3/Q4 2025. Daily trading behavior and volume patterns suggest steady accumulation, with technical structure increasingly favorable for medium-term investors.
Fundamental analysis
Pfizer’s core fundamentals remain robust and competitive. Its trailing twelve-month revenue reached $62.46 billion, with a net profit of $7.87 billion and an EBITDA of $23.32 billion. While top-line revenue in Q1 2025 was $13.72 billion (down 7.8% year-on-year due to reduced COVID-19 product sales), the company still achieved earnings upside, thanks to margin discipline and an agile cost base. Annual dividend yield stands at an attractive 6.76%, distributed quarterly, making Pfizer one of the most reliable income plays among global blue chips.
Valuation metrics underscore renewed interest: a P/E ratio of 18.57 is notably attractive relative to peers, especially given Pfizer’s sector leadership and extensive research & development (R&D) pipeline. Forward guidance points to projected 2025 revenue of $61–64 billion and adjusted EPS between $2.80 and $3.00, reaffirming the long-term growth profile. Structural advantages—such as global brand stature, robust R&D spend, and a pipeline encompassing 108 active drugs in all clinical stages—fortify Pfizer’s ability to adapt and lead.
- Market-leading presence in oncology, vaccines, and inflammation/immunology
- Successful track record of late-stage product launches and regulatory approvals
- Global distribution reach, with operations in 175+ countries
- Continuous investment in precision medicines and next-generation therapies
Volume and liquidity
Pfizer’s shares are characterized by deep market liquidity and resilient investor confidence. The average three-month trading volume exceeds 44.22 million shares, placing it among the most liquid healthcare stocks traded on the NYSE. With total shares outstanding at 5.69 billion, ample free float ensures efficient price discovery, dynamic turnover, and ease of entry or exit for investors of all sizes—including institutional and Philippine retail participants.
Liquidity is further bolstered by strong global coverage, large institutional holdings, and defensive market positioning. This high degree of tradability reduces transaction risk, making Pfizer ideal for investors seeking exposure to the healthcare sector with minimal liquidity constraints.
Catalysts and positive outlook
- A robust pipeline, with 47 drugs in Phase 1, 28 in Phase 2, 30 in Phase 3, and 3 under regulatory review
- Late-stage clinical results and up to 8 major data readouts, plus 4 expected regulatory decisions in 2025—likely to generate positive headlines and upward price action
- Expanding in cancer therapies and vaccines, with breakthrough innovations such as ABRYSVO for respiratory syncytial virus (RSV) infections
- Aggressive operational efficiency, targeting $4.5 billion in cost reductions by end-2025, improving profitability and funding further R&D investment
- Strong ESG profile, with ongoing sustainability initiatives and ethical leadership
- Supportive healthcare policy both globally and in emerging markets, driving access to innovative medicines
The company’s recent ability to beat consensus on earnings, combined with analyst projections for a 13.75% potential upside toward $28.11 (with upper targets near $33), signals renewed optimism. In a fast-evolving healthcare environment, Pfizer’s leadership, diversified drug portfolio, and scale set it apart.
Investment strategies
- Short-term: Tactical investors may find opportunity in technical pullbacks near key support (~$25.10–$25.23), ahead of Q2 and Q3 earnings, or before major data releases that regularly catalyze upside moves.
- Medium-term: Investors can position for pipeline catalysts and regulatory decisions, with an eye on dividend capture and potential sector rotation into healthcare as global macro conditions fluctuate.
- Long-term: For those seeking consistent returns and defensive balance, Pfizer’s dividend, large-cap stability, and ongoing innovation create a strong anchor for diversified portfolios—including Philippine investors looking for US dollar revenue exposure.
For all entry strategies, accumulating shares as the stock tests support levels or after positive earnings or clinical announcements may enhance the risk/reward trade-off. Regardless of approach, Pfizer’s liquidity and global profile ease position sizing and potential portfolio rebalancing.
Is it the right time to buy Pfizer?
Pfizer stands out as a rare blend of innovative strength, reliable dividends, and technical momentum—all in one blue-chip package. The stock’s current valuation, robust pipeline, and historical resilience signal it may be primed for a new bullish phase. Forward-looking investors have strong justification for renewed interest, as each catalyst and earnings season reinforces the long-term upside.
While all equity investments require ongoing assessment, Pfizer seems to represent an excellent opportunity for those seeking both income and growth, offering broad exposure to global health trends with a proven track record of stability and innovation. The present convergence of technical signals, market support, and strategic catalysts underscores why Pfizer deserves careful consideration from any investor aiming to capitalize on the next cycle in healthcare leadership.
Ultimately, Pfizer’s potential, liquidity, and powerful innovation pipeline make it an ideal candidate for those aiming to benefit from the enduring growth of the healthcare sector—now and well into the future.
How to Buy Pfizer Stock in the Philippines
Buying Pfizer stock online is straightforward and secure when you use a regulated broker in the Philippines. You can choose between two main methods: spot buying, where you purchase real Pfizer shares, or CFD trading, which lets you speculate on price movements with leverage. Each method has its advantages, depending on your goals and experience. For those ready to take the next step, a detailed broker comparison is available further down the page.
Spot buying
A cash purchase of Pfizer stock means buying actual shares on the NYSE and holding them in your account. You typically pay a fixed commission per order, which for Philippine brokers is usually about $5 to $10 or the peso equivalent.
Gain scenario
For example, if the Pfizer share price is $25.55, with a $1,000 investment you can buy around 39 shares, including a brokerage fee of about $5.
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.
Cash buying is recommended for investors seeking real ownership and eligibility for Pfizer's generous dividends.
Trading via CFD
CFD (Contract for Difference) trading lets you speculate on Pfizer’s price movements without owning the actual shares. This method allows you to use leverage, increasing your potential gains or losses. You’ll pay a spread (the buy-sell difference) and, if you hold overnight, a small financing charge.
Example of a leveraged CFD trade
You open a CFD position on Pfizer shares with a $1,000 stake and 5x leverage. This gives you market exposure of $5,000. ✔️ Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +$400 gain, on a bet of $1,000 (excluding fees).
CFDs are best suited for experienced investors seeking to take advantage of short-term market movements.
Final advice
Before investing, be sure to compare brokers’ fees, trading platforms, and available features using the comparison tool further down the page. The best choice between spot buying and CFD trading depends on your personal goals and risk tolerance. Understanding your options can help you get started investing confidently in Pfizer and building a strong portfolio for the future.
Compare the best brokers in the Philippines!Compare brokersOur 7 Tips for Buying Pfizer Stock
| 📊 Step | 📝 Specific tip for Pfizer |
|---|---|
| Analyze the market | Study global health trends and how US and PH regulations can impact Pfizer’s opportunities. |
| Choose the right trading platform | Select a PH-approved broker with access to US stocks and favorable dollar funding options. |
| Define your investment budget | Decide how much to invest, keeping in mind currency risk and portfolio diversification. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Pfizer’s strong dividend and pipeline. |
| Monitor news and financial results | Track Pfizer’s clinical trials, earnings, and regulatory news as they drive stock movements. |
| Use risk management tools | Use stop-loss orders and review your Pfizer investment regularly based on your risk profile. |
| Sell at the right time | Reassess your position after major drug approvals, earnings, or when reaching personal targets. |
The latest news about Pfizer
Pfizer maintains its significant presence in the Philippines with a stable portfolio of distributed vaccines and medicines. The company actively supports local public health through strategic partnerships and regulatory compliance, ensuring access to essential treatments and strengthening its market profile in the country.
Pfizer’s latest quarterly results exceeded EPS expectations and confirmed robust innovation momentum. For Q1 2025, Pfizer posted an adjusted EPS of $0.92, surpassing forecasts, and reinforced forward guidance for 2025, underlining strong R&D outcomes. This result resonates positively for institutional investors monitoring consistency in core performance.
Pfizer’s dividend yield is among the highest in the global pharma sector at 6.76%. The current $0.43 per share quarterly payout supports reliable income for global investors, including those in the Philippines, and reflects the company’s ongoing shareholder return policy as part of its post-pandemic capitalization strategy.
Technical indicators suggest renewed buying interest in Pfizer stock following a sustained consolidation phase. Trading above all key moving averages, Pfizer’s technical setup now signals a potential medium-term uptrend, attracting attention from investors seeking both income and growth.
Major pipeline developments in 2025 strengthen Pfizer’s long-term outlook for the Asia-Pacific region. Ongoing launches in vaccines and oncology, with several Phase 3 programs advancing, are expected to enhance the company’s leadership and product access in the Philippines and neighboring markets.
FAQ
What is the latest dividend for Pfizer stock?
Pfizer currently pays a regular dividend. The most recent declared dividend is $0.43 per share, with the next ex-dividend date set for July 25, 2025. This gives Pfizer one of the highest yields in the pharma sector, reflecting a long-standing policy of steady, shareholder-friendly payouts. The company has a track record of maintaining and gradually growing its dividend over time.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current price, the projected values for Pfizer stock are $33.22 at the end of 2025, $38.33 at the end of 2026, and $51.10 at the end of 2027. This outlook is supported by Pfizer’s robust pipeline, expected cost savings, and new launches in vaccines and oncology. Analysts see potential for price appreciation as the company invests in innovation and expands in emerging markets.
Should I sell my Pfizer shares?
Holding on to Pfizer shares appears justified given its strong fundamentals, market leadership, and resilient dividend policy. The current valuation is attractive relative to historical levels, and the firm’s pipeline is rich in upcoming catalysts. For investors seeking stability and reliable income, Pfizer’s mid- to long-term prospects remain persuasive, especially as healthcare demand continues to rise globally.
How are dividends and capital gains from Pfizer stock taxed for PH investors?
For investors in the Philippines, dividends from Pfizer are subject to a U.S. withholding tax—typically 30%, unless reduced by a tax treaty. Capital gains on foreign shares are usually not taxed locally, but it is important to declare returns according to Philippine regulations. Always check with a licensed tax professional for the latest policy and reporting requirements.
What is the latest dividend for Pfizer stock?
Pfizer currently pays a regular dividend. The most recent declared dividend is $0.43 per share, with the next ex-dividend date set for July 25, 2025. This gives Pfizer one of the highest yields in the pharma sector, reflecting a long-standing policy of steady, shareholder-friendly payouts. The company has a track record of maintaining and gradually growing its dividend over time.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current price, the projected values for Pfizer stock are $33.22 at the end of 2025, $38.33 at the end of 2026, and $51.10 at the end of 2027. This outlook is supported by Pfizer’s robust pipeline, expected cost savings, and new launches in vaccines and oncology. Analysts see potential for price appreciation as the company invests in innovation and expands in emerging markets.
Should I sell my Pfizer shares?
Holding on to Pfizer shares appears justified given its strong fundamentals, market leadership, and resilient dividend policy. The current valuation is attractive relative to historical levels, and the firm’s pipeline is rich in upcoming catalysts. For investors seeking stability and reliable income, Pfizer’s mid- to long-term prospects remain persuasive, especially as healthcare demand continues to rise globally.
How are dividends and capital gains from Pfizer stock taxed for PH investors?
For investors in the Philippines, dividends from Pfizer are subject to a U.S. withholding tax—typically 30%, unless reduced by a tax treaty. Capital gains on foreign shares are usually not taxed locally, but it is important to declare returns according to Philippine regulations. Always check with a licensed tax professional for the latest policy and reporting requirements.
On the same topic
